Emerging therapies for urothelial cancer

César Serrano; Rafael Morales; Cristina Suárez; Isaac Núñez; Claudia Valverde; Jordi Rodón; Jordi Humbert; Olga Padrós; Joan Carles

doi:10.1016/j.ctrv.2011.10.007

Emerging therapies for urothelial cancer

César Serrano, Rafael Morales, Cristina Suárez, Isaac Núñez, Claudia Valverde, Jordi Rodón, Jordi Humbert, Olga Padrós, Joan Carles

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials.

Original language	English (US)
Pages (from-to)	311-317
Number of pages	7
Journal	Cancer treatment reviews
Volume	38
Issue number	4
DOIs	https://doi.org/10.1016/j.ctrv.2011.10.007
State	Published - Jun 2012
Externally published	Yes

Keywords

Anti-EGFR
Bladder cancer
Emerging treatments
Eribulin
MTOR inhibition
Nab-paclitaxel
PARP
Sorafenib
Sunitinib
Volasertib

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2011.10.007

Cite this

@article{72e33d1d43a340cbb7690c6b8b30f792,

title = "Emerging therapies for urothelial cancer",

abstract = "Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials.",

keywords = "Anti-EGFR, Bladder cancer, Emerging treatments, Eribulin, MTOR inhibition, Nab-paclitaxel, PARP, Sorafenib, Sunitinib, Volasertib",

author = "C{\'e}sar Serrano and Rafael Morales and Cristina Su{\'a}rez and Isaac N{\'u}{\~n}ez and Claudia Valverde and Jordi Rod{\'o}n and Jordi Humbert and Olga Padr{\'o}s and Joan Carles",

year = "2012",

month = jun,

doi = "10.1016/j.ctrv.2011.10.007",

language = "English (US)",

volume = "38",

pages = "311--317",

journal = "Cancer treatment reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Emerging therapies for urothelial cancer

AU - Serrano, César

AU - Morales, Rafael

AU - Suárez, Cristina

AU - Núñez, Isaac

AU - Valverde, Claudia

AU - Rodón, Jordi

AU - Humbert, Jordi

AU - Padrós, Olga

AU - Carles, Joan

PY - 2012/6

Y1 - 2012/6

N2 - Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials.

AB - Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials.

KW - Anti-EGFR

KW - Bladder cancer

KW - Emerging treatments

KW - Eribulin

KW - MTOR inhibition

KW - Nab-paclitaxel

KW - PARP

KW - Sorafenib

KW - Sunitinib

KW - Volasertib

UR - http://www.scopus.com/inward/record.url?scp=84859160304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859160304&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2011.10.007

DO - 10.1016/j.ctrv.2011.10.007

M3 - Review article

C2 - 22113129

AN - SCOPUS:84859160304

SN - 0305-7372

VL - 38

SP - 311

EP - 317

JO - Cancer treatment reviews

JF - Cancer treatment reviews

IS - 4

ER -

Emerging therapies for urothelial cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this